financetom
Business
financetom
/
Business
/
--First Financial Keeps Quarterly Dividend at $0.51 a Share, Payable July 15 to Shareholders of Record July 1
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--First Financial Keeps Quarterly Dividend at $0.51 a Share, Payable July 15 to Shareholders of Record July 1
Jun 18, 2025 11:27 AM

02:07 PM EDT, 06/18/2025 (MT Newswires) --

Price: 50.96, Change: +0.20, Percent Change: +0.39

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--TFS Financial Maintains Dividend at $0.2825 per Share, Payable on June 25 to Shareholders of Record on June 11
--TFS Financial Maintains Dividend at $0.2825 per Share, Payable on June 25 to Shareholders of Record on June 11
May 31, 2024
04:58 AM EDT, 05/31/2024 (MT Newswires) -- Price: 12.78, Change: -0.31, Percent Change: -2.37 ...
American International Group Prices Secondary Offering of Corebridge Financial Targeting $876 Million in Gross Proceeds
American International Group Prices Secondary Offering of Corebridge Financial Targeting $876 Million in Gross Proceeds
May 31, 2024
04:49 AM EDT, 05/31/2024 (MT Newswires) -- American International Group ( AIG ) said Thursday it priced a secondary offering of Corebridge Financial ( CRBG ) common shares at $29.20 per share. As the selling stockholder, American International has offered 30 million common shares out of about 608 million shares outstanding of Corebridge Financial ( CRBG ), targeting gross proceeds...
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months
May 31, 2024
04:49 AM EDT, 05/31/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday the US Food and Drug Administration has extended until Sept. 27 the action date on the biologics license application for Dupixent as a supplemental maintenance treatment in adults with uncontrolled chronic obstructive pulmonary disease. The three-month extension comes after the FDA...
Prelude Therapeutics Files for $400 Million Mixed Shelf
Prelude Therapeutics Files for $400 Million Mixed Shelf
May 31, 2024
04:54 AM EDT, 05/31/2024 (MT Newswires) -- Prelude Therapeutics ( PRLD ) filed Thursday a registration statement covering the potential sale of up to $400 million of securities from time to time. The securities include common stock, preferred stock, debt securities, warrants, subscription rights and units. Unless otherwise provided in a prospectus supplement, the company said it expects to use...
Copyright 2023-2026 - www.financetom.com All Rights Reserved